Stockscreener 앱 받기
112.46
1.79%
-2.05
시간 외 거래:
112.50
0.04
+0.04%
Gilead Sciences Inc 주식(GILD)의 최신 뉴스
Tango (TNGX) Q2 Revenue Drops 52% - The Motley Fool
FDA Rejects Replimune’s Cancer Therapy as San Diego Biotech Sector Faces Layoffs and Gilead Reports Progress on HIV Prevention Injectable - geneonline.com
HIV patient advocacy group sues Trump administration over Gilead settlement - The Business Journals
Gilead Sciences Reports Earnings Thursday. Can The Highly Ranked Drugmaker Beat Its 237% Profit Surge Last Quarter? - Investor's Business Daily
Inside “The Time Is Now: Let’s End HIV In Our Communities” Press Briefing Presented By Gilead Sciences - essence.com
Gilead Sciences Completes Promising Phase III Study on Urothelial Cancer Treatment - TipRanks
Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts? - TradingView
Morgan Stanley Remains Bullish on Gilead Sciences (GILD) - Insider Monkey
The story behind the Replimune rejection, and San Diego sees a biotech winter - statnews.com
Seeking Clues to Gilead (GILD) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics - Nasdaq
Gilead Sciences Reports Earnings Thursday. Can The… - inkl
What are analysts’ price targets for Gilead Sciences Inc. in the next 12 monthsCapitalize on market shifts before others do - Jammu Links News
Is Gilead Sciences Inc. stock overvalued or undervaluedFree Stock Selection - Jammu Links News
How many analysts rate Gilead Sciences Inc. as a “Buy”Rapidly expanding wealth - jammulinksnews.com
How does Gilead Sciences Inc. compare to its industry peersBuild wealth faster with high-performing stocks - Jammu Links News
The Bull Case For Gilead Sciences (GILD) Could Change Following EMA Backing For Lenacapavir PrEP - simplywall.st
Why is Gilead Sciences Inc. stock attracting strong analyst attentionBuild wealth steadily with proven methods - jammulinksnews.com
Should I hold or sell Gilead Sciences Inc. stock in 2025Outstanding investment returns - Jammu Links News
Why Gilead Sciences Stock Just Popped - AOL.com
Gilead Sciences gets USFDA nod for new Biktarvy indication for people with HIV who are treatment... - Medical Dialogues
AIDS activists sue HHS to obtain Gilead settlement over patents for HIV prevention pills - statnews.com
Pheton Holdings Dismisses Rumors Of Acquisition By Gilead, But Retail’s Extremely Optimistic - Stocktwits
Pheton Holdings Ltd Issues Statements Addressing Recent Market Activity and Misleading Rumors - Stock Titan
This Gilead Sciences Insider Reduced Their Stake By 19% - 富途牛牛
Gilead Employees Give Back During Month of Service - Gilead Sciences
Trump targets Genentech, Gilead in 'most favored nation' drug-pricing decreeSan Francisco Business Times - The Business Journals
Gilead and Arcus Advance Promising Colorectal Cancer Study - TipRanks
Two Shots A Year: How A New HIV Drug Is Tackling Stigma And Saving Lives - Forbes
Gilead Sciences Advances Pediatric Hepatitis B Treatment with TAF Study Update - TipRanks
Gilead’s Promising Phase 3 Study in Metastatic Breast Cancer: A Potential Game Changer - TipRanks
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Are Wall Street Analysts Bullish On Gilead Sciences Stock? - Barchart.com
How Dr. Toyin Nwafor of Gilead targets HIV disparities - Rolling Out
What data driven models say about Gilead Sciences Inc.’s futureChart Breakout Buy Signal Detection Confirmed - metal.it
Gilead and Arcus Advance Cancer Treatment Study with AB308 and Zimberelimab - TipRanks
Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now? - MSN
Gilead files covid 19 remdesivir actions against Chinese military research institute - IAM Patent
NY Judge Faces Recusal Request Over Gilead Stock Holdings - Law360
Gilead Sciences’ TAF Study in Children with Hepatitis B: An Update - TipRanks
BMO says WSJ report on RFK potential headwind for Gilead - Yahoo Finance
AbbVie, Gilead and GSK back World Hepatitis Day, seeking to tackle stigma to drive elimination - Fierce Pharma
Gilead Sciences’ Strategic Positioning and Growth Prospects in the HIV Prevention Market Justify Buy Rating - TipRanks
Gilead price collects profitsForecast today29-07-2025 - Economies.com
Integrase Inhibitors Market Growth and Future Scope 2025-2032 | - openPR.com
Order Flow Trends Show Accumulation in Gilead Sciences Inc.Long Hold Safe Return Strategy Reviewed - metal.it
What are the technical indicators suggesting about Gilead Sciences Inc.Post Market Planner That Work - jammulinksnews.com
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Why Gilead Sciences Stock Slipped Today - AOL.com
Gilead down as analysts see RFK Jr. preventative task force action negatively - Seeking Alpha
Gilead Sciences stock falls amid reports of preventive health panel dismissal - Investing.com
BMO Capital Has An Important Take On Gilead Sciences, Retail’s Keeping The Optimism Alive - Stocktwits
Citi Maintains a Buy Rating on Gilead Sciences (GILD) - MSN
TD Cowen Remains Bullish on Gilead Sciences (GILD) - Insider Monkey
What is Gilead Sciences Inc. company’s growth strategyFree Predictions - jammulinksnews.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc.GILD - PR Newswire
Does Gilead Sciences (NASDAQ:GILD) Have A Healthy Balance Sheet? - simplywall.st
Lenacapavir: After FDA approval, HIV pre-exposure prophylaxis injectable moving closer to EU approval - The Hindu
Gilead Sciences Stock Surges Amid Promising Trials - TipRanks
10 Most Profitable Biotech Stocks to Invest in Now - Insider Monkey
European Medicines Agency Recommends Lenacapavir (Yeztugo) Injectable PrEP for HIV Prevention - Contagion Live
5.18%
3.26%
자본화:
|
볼륨(24시간):